10-K: Kestra Medical Technologies Reports Soaring FY2025 Revenue Amidst Continued Strategic Investments and Net Losses

Kestra Medical Technologies, a commercial-stage medical device company, announced a significant 115% surge in revenue for the fiscal year ended April 30, 2025, driven by strong adoption of its ASSURE WCD, despite reporting increased net losses as it continues to invest heavily in growth and infrastructure.

Summary

• Revenue for the fiscal year ended April 30, 2025, increased by 115% to $59.8 million, up from $27.8 million in the prior fiscal year.
• The company reported a net loss of $113.8 million for FY2025, compared to a net loss of $94.1 million for FY2024.
• Gross profit significantly improved to $24.2 million for FY2025, a substantial increase from $0.4 million in FY2024.
• As of April 30, 2025, the accumulated deficit reached $520.2 million.
• Cash and cash equivalents stood at $237.6 million as of April 30, 2025, a significant increase from $8.2 million in FY2024, primarily due to proceeds from the Initial Public Offering (IPO).
• The company completed its IPO on March 7, 2025, raising $215.8 million in net proceeds.
• The ASSURE WCD, the cornerstone of the Cardiac Recovery System platform, received FDA approval in July 2021 and was fully commercially launched in August 2022, having been worn by over 20,000 patients.
• Clinical data from the ACE-PAS study (July 2024 submission, 5,929 patients) showed a 96% first shock conversion efficacy, a median daily use of 23.2 hours, and a low false alarm rate of 6% compared to 46% for the competitor's device.
• The estimated annual addressable market is approximately $10 billion in the U.S. and $14 billion internationally, based on patient populations and reimbursement rates.
• Over 285 million U.S. lives are covered by insurance contracts for the ASSURE WCD as of April 30, 2025, representing approximately 90% of total available lives.
• Medicare reimbursement rates for WCDs have increased at a CAGR of 4.7% from 2021 to 2025.
• The company's headcount grew from 66 in October 2020 to over 330 as of April 30, 2025, including a commercial sales team of approximately 80 direct sales representatives and over 300 contracted patient specialists.
• The company holds rights to over 365 pending and issued patents worldwide.
• Outstanding debt under the Term Loan 2024 was approximately $45.0 million as of April 30, 2025.

Sentiment

Score: 7

Explanation: The company demonstrates strong revenue growth and significant improvements in gross profit, driven by increased patient adoption and favorable clinical data for its differentiated product. The successful IPO has substantially improved liquidity. However, it continues to incur significant net losses and operates in a competitive, highly regulated environment with identified material weaknesses in internal controls, which are being remediated. The overall outlook is positive due to market opportunity and product advantages, but profitability is not yet achieved.

Positives

• Revenue increased by 115% year-over-year to $59.8 million for the fiscal year ended April 30, 2025, indicating strong market penetration and adoption.
• Gross profit saw a substantial increase to $24.2 million for FY2025, up from $0.4 million in FY2024, reflecting improved operational efficiency and reimbursement realization.
• The ASSURE WCD has been worn by over 20,000 patients since its full commercial launch, demonstrating growing patient and provider acceptance.
• Clinical evidence from the ACE-PAS study highlights superior product performance with a 96% first shock conversion efficacy and a significantly lower false alarm rate of 6% compared to the competitor's 46%.
• The company has secured broad payor coverage, covering over 285 million U.S. lives (approximately 90% of the total available lives), which is crucial for market access.
• Medicare reimbursement rates for WCDs have shown a favorable trend, increasing at a CAGR of 4.7% from 2021 to 2025.
• The company successfully completed its IPO, raising $215.8 million in net proceeds, significantly bolstering its cash reserves to $237.6 million.
• The introduction of the ASSURE wearable ECG, cleared by the FDA in May 2024 and commercially launched in September 2024, expands the company's product offerings into adjacent cardiac monitoring markets.
• Investments in infrastructure, including a scalable supply chain and revenue cycle management capabilities, are expected to drive operational efficiency and support future growth.
• The company possesses a robust intellectual property portfolio with over 365 pending and issued patents worldwide, creating a high barrier to entry.
• FDA approval in May 2024 for a therapy cable repair program and extension of battery useful life from two to six years contributed to a reduction in depreciation expense by $1.2 million and $0.198 million respectively, improving cost of revenue.

Negatives

• The company continues to incur significant net losses, with a net loss of $113.8 million in FY2025, an increase from $94.1 million in FY2024.
• An accumulated deficit of $520.2 million as of April 30, 2025, indicates a history of unprofitability.
• The company has a limited operating history, with its full commercial launch in August 2022, making it challenging to evaluate long-term success and viability.
• Identified material weaknesses in internal control over financial reporting, which are still undergoing remediation and are expected to extend beyond FY2025, could impair timely and accurate financial statements.
• The business is highly dependent on the ASSURE WCD for revenue, posing a concentration risk.
• Reliance on a limited number of third-party suppliers and contract manufacturers creates vulnerability to supply shortages and price fluctuations.
• Billing for products is complex, requiring substantial time and resources, and is subject to uncertainties in reimbursement and potential audits.
• The company faces competition from an incumbent product (ZOLL's LifeVest WCD) and a new market entrant, which could impact market share and pricing.
• Seasonality in billings and collections, particularly in January and February due to resetting annual patient healthcare insurance plan deductibles, can lead to fluctuations in financial results.
• The company does not currently maintain cyber insurance, exposing it to potential unmitigated losses from security events.

Risks

• Limited operating history makes it difficult to evaluate current business and likelihood of success, with potential for unforeseen expenses, difficulties, and delays.
• Continued history of net losses and no assurance of achieving profitability, potentially requiring future equity or debt financing which may not be available on favorable terms.
• High dependence on the ASSURE WCD for continued success, making the business vulnerable to factors affecting its adoption and reimbursement.
• Commercial success relies on healthcare provider, hospital, and patient adoption, which may be hindered by reluctance to change practice patterns or perceived high pricing.
• Failure to obtain and maintain broad coverage and adequate reimbursement levels from governmental authorities and health insurers could limit marketability and profitability.
• Inability to manage anticipated business growth effectively could harm future revenue and operating results.
• Clinical study initiatives are complex, lengthy, expensive, and carry uncertain outcomes; future trials may fail to replicate positive results observed to date.
• Dependence on a limited number of third-party suppliers and contract manufacturers could lead to supply shortages, price fluctuations, and manufacturing delays.
• Billing for products is complex, requiring substantial time and resources, and is subject to potential contractual adjustments, long collection cycles, and increased audits.
• Competitors may develop or market more effective products or gain greater acceptance, reducing commercial opportunities.
• Identified material weaknesses in internal control over financial reporting, if not effectively remediated, could impair the ability to produce timely and accurate financial statements.
• Third parties may assert intellectual property infringement claims, leading to costly, time-consuming, or unsuccessful litigation, hindering commercialization.
• Efforts to obtain and maintain intellectual property protection may be inadequate, or rights may be challenged, adversely affecting the business.
• Changes in the regulatory environment may make it more difficult and costly to manufacture, market, or distribute products, or obtain approvals for future products.
• Failure to comply with healthcare and other governmental regulations could result in substantial penalties, including fines, imprisonment, or exclusion from healthcare programs.
• Bain Capital's significant influence over the company, with its interests potentially conflicting with those of other shareholders.
• Estimates relating to market size and forecasts of market growth are based on complex assumptions and may prove inaccurate.
• Macroeconomic conditions, such as high inflation and interest rates, could materially adversely affect business, financial condition, and results of operations.
• Annual effective income tax rate can change materially due to changes in the mix of U.S. and non-U.S. earnings, tax laws, or challenges to transfer pricing arrangements.
• Risk of being required to reclassify independent contractors as employees, incurring additional costs and taxes.
• Exposure to potential product liability claims inherent in medical device provision, which could lead to costly litigation and reputational harm.
• Inability to support demand for current or future products or services due to scaling challenges could harm business.
• Loss of key senior management or inability to attract and retain highly skilled employees could harm the business.
• Security breaches, loss of data, unauthorized uses or disclosures, and other disruptions involving systems, products, or data could compromise sensitive information and expose the company to liability.
• Failure to maintain required licenses, certifications, or accreditation, or comply with notification requirements for ownership changes, could adversely impact operations.
• Compliance with environmental laws and regulations could be expensive, and non-compliance could result in significant liability.
• Products contain third-party open source software components, and failure to comply with licenses could restrict sales or affect proprietary information.
• Share price may be volatile and decline disproportionately to operating performance due to various market and company-specific factors.
• Potential classification as a passive foreign investment company (PFIC) could result in adverse U.S. federal income tax consequences for U.S. Holders.
• Sale of a substantial number of shares by affiliates after lock-up expiration may cause the share price to decline.
• Difficulty for shareholders to enforce judgments against the company or its directors/executive officers in Bermuda due to differences in legal systems.
• Anti-takeover provisions in amended and restated bye-laws may discourage a change of control, even if beneficial to shareholders.
• Exclusive forum provisions in amended and restated bye-laws may discourage certain lawsuits against directors and officers.
• No expectation of cash dividends in the foreseeable future, limiting return on investment to share price appreciation.
• Future securities issuances could result in significant dilution to shareholders and impair the market price of common shares.
• Increased costs and management time associated with operating as a public company.
• If securities or industry analysts do not publish research or publish negative reports, share price and trading volume could decline.

Future Outlook

The company expects revenue to continue increasing as the number of patients using its product grows. It anticipates research and development expenses to decrease as a percentage of revenue, while overall selling, general and administrative expenses are expected to increase in absolute terms due to headcount growth but decrease as a percentage of revenue. Management believes existing cash and cash equivalents, combined with future revenue, will be sufficient to fund operating and capital needs for at least the next 12 months. The company plans to pursue CE Mark approval in Europe and strategically commercialize in select Western European countries within the next three years. Long-term vision includes expanding offerings to a broader range of cardiac patients and leveraging data from the ASSURE Patient Registry to develop advanced algorithms for personalized clinical decision support.

Management Comments

• We believe the ASSURE WCD offers significant clinical and functional advantages, including greater patient compliance as a result of a major reduction in false alarms and enhanced comfort and wearability.
• We believe our Cardiac Recovery System platform addresses serious unmet needs in the cardiac patient population and has the potential to disrupt and grow the market which has been limited to a single solution for more than 20 years.
• We believe our significant investments in infrastructure create a high barrier to entry that will help us protect and grow our market share.
• We believe the combination of our intellectual property portfolio and upgradeable product design creates significant opportunities for efficient innovation.
• Based on feedback from our payors, we believe that this reflects payors desire for a second choice to the competitor product, our solution addressing an unmet need with a female-specific garment and the overall patient compliance benefits of the ASSURE WCD.
• We remain confident that our Cardiac Recovery System platform will continue to be advantaged in the market due to our differentiated and integrated features enabling superior patient comfort, compliance, connectivity and support.
• We believe that our existing cash and cash equivalents and cash generated from revenue transactions with customers will be sufficient to fund our operating and capital needs for at least the next 12 months.

Industry Context

The Wearable Cardioverter Defibrillator (WCD) market has historically been dominated by a single incumbent product, ZOLL's LifeVest WCD, for over two decades. Kestra Medical Technologies, with its FDA-approved ASSURE WCD, is positioned as a next-generation alternative aiming to disrupt this market. The global WCD market reached $1.3 billion in 2023, with the U.S. accounting for approximately 85% of revenues. Despite proven efficacy, WCD therapy remains significantly underutilized, reaching only 14% of eligible U.S. patients, largely due to limitations of the legacy device such as high false alarms and discomfort. The entry of Kestra's ASSURE WCD and a recent new adhesive-based external defibrillator indicate increasing competition and innovation in this space, with Kestra focusing on addressing the unmet needs for patient comfort and compliance to drive broader market adoption.

Comparison to Industry Standards

• The ASSURE WCD's false alarm rate of 6% is significantly lower than the competitor's device (LifeVest WCD), which reported a 46% false alarm rate in a published study.
• The ASSURE WCD delivers a 170 joule shock, which is higher than the competitor device's 150 joule shock, potentially offering better efficacy for patients with higher defibrillation thresholds.
• The ASSURE WCD provides a minimum defibrillation capacity of 25 shocks, offering a significant safety buffer for patients experiencing multiple cardiac events, which is a competitive advantage.
• The company's garments are designed with gender-specific styles and a wide range of sizes, directly addressing the discomfort and poor wearability issues associated with the competitor's unisex-only garment.
• The ASSURE WCD's median daily wear time of 23.2 hours demonstrates high patient compliance, contrasting with findings for the competitor's device where a significant percentage of patients had zero daily wear time.
• The ASSURE WCD utilizes four channels of high-quality ECG with Adaptive Patient Intelligence (API) for improved signal quality and noise reduction, compared to the competitor's two channels which can lead to noisy data.

Management Changes

Corporate Governance

Legal Proceedings

• The company is from time to time a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of business.
• Management does not expect any of its pending legal proceedings to have a material adverse effect on its results of operations, financial position, or cash flows.
• There is no active litigation involving any of the company's patents or other intellectual property rights, and no notices of patent infringement have been received.

Related Party Transactions

• Bain Capital beneficially owns approximately 52.6% of the company's common shares and controls approximately 48.6% of the voting power, giving it significant influence over corporate decisions.
• The company's amended and restated bye-laws include provisions that renounce any interest or expectancy in business opportunities presented to Bain Capital and its affiliates, even if the company might reasonably have pursued them.
• Bain Capital and its affiliates do not have any duty to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as the company.
• Payments of administrative costs to third parties on behalf of West Affum Holdings, L.P. (the direct parent prior to IPO) totaled $4.878 million in FY2025 and $0.799 million in FY2024, recorded as deemed dividends.
• Warrants were issued to lenders (Perceptive Credit Holdings IV, LP and Kennedy Lewis Capital Partners Master Fund II LP) in connection with term loans, initially to purchase common units of West Affum Holdings, L.P., which were subsequently exchanged for common shares of Kestra Medical Technologies, Ltd. upon the IPO.

Stakeholder Impact

• Shareholders: Face potential dilution from future equity issuances, share price volatility, and limited ability to enforce judgments in Bermuda due to differing legal frameworks. Bain Capital's significant influence may lead to conflicts of interest. No cash dividends are expected in the foreseeable future.
• Employees: Benefit from a compensation program designed to attract and retain talent, including a 401(k) plan with company contributions. However, they are subject to a clawback policy for incentive-based compensation and risks related to high turnover and competition for skilled personnel.
• Customers (Healthcare Providers/Hospitals): Benefit from the ASSURE WCD's improved comfort, compliance, and integrated digital solutions. Supported by a direct sales team and patient specialists. May face challenges with billing complexities and potential reluctance to adopt new products.
• Patients: Directly benefit from the ASSURE WCD's safety, efficacy, and comfort features, as well as integrated digital health services like the patient app and remote monitoring. Risks include potential product liability claims and the need for consistent device compliance.
• Suppliers/Creditors: The company relies on a limited number of third-party manufacturing and supply partners, creating risks of supply shortages or price fluctuations. Creditors are impacted by the company's debt obligations under the Term Loan 2024.

Next Steps

• Continue to capture market share of current WCD prescriptions in the U.S. by expanding the commercial organization and fostering advocacy.
• Expand adoption of the Cardiac Recovery System platform in the U.S. to increase market penetration through targeted market-shaping strategies and educating healthcare providers.
• Build upon the strong base of clinical evidence, with anticipated additional publications from the ongoing ASSURE Patient Registry.
• Continue payor engagement to broaden coverage and increase reimbursement, focusing on state and smaller regional plans.
• Innovate the system and bolster the digital healthcare platform and data management capabilities, including developing advanced algorithms for personalized clinical decision support.
• Drive gross profit expansion and operating leverage through supply chain efficiencies and manufacturing process enhancements.
• Pursue expansion in international markets, planning for CE Mark approval in Europe and strategic commercialization in select Western European countries within the next three years.
• Strategically pursue adjacent markets with new product offerings and differentiated services, such as the ASSURE wearable ECG.
• Remediate identified material weaknesses in internal control over financial reporting, with full remediation expected beyond the fiscal year ended April 30, 2025.

Key Dates

Recommendation

Keywords

Wearable Cardioverter Defibrillator, WCD, Cardiac Recovery System, Medical Device, Cardiovascular Disease, Sudden Cardiac Arrest, SCA, FDA Approval, Reimbursement, Digital Health, Patient Monitoring, Electrophysiology, Healthcare Technology, IPO, SEC Filing, 10-K, ASSURE WCD, Kestra Medical Technologies